头孢地尔对多重耐药革兰阴性菌高风险克隆的体外活性
头孢地尔显示出强效体外活性,98%的菌株在≤4 mg/L被抑制,且是对该菌株集合最活跃的抗菌药物。
要点
- 头孢地尔对多重耐药革兰阴性菌临床分离株体外活性优异。
- 98%的菌株头孢地尔MIC≤4 mg/L。
- 产KPC-3肺炎克雷伯菌均对头孢地尔敏感,包括耐头孢他啶/阿维巴坦者。
核心结论
- 头孢地尔对多重耐药革兰阴性菌(包括碳青霉烯耐药分离株)表现出优异活性,且是所测抗菌药物中对本菌株集合最活跃者。
研究设计与样本
- 菌株包括125株肠杆菌目(121株产ESBL和/或碳青霉烯酶的肺炎克雷伯菌,4株产碳青霉烯酶的阴沟肠杆菌)、80株鲍曼不动杆菌、6株铜绿假单胞菌和20株嗜麦芽窄食单胞菌。
- 采用CLSI指南推荐的肉汤微量稀释法测定MIC,头孢地尔使用铁缺乏CAMHB,其他抗菌药物使用CAMHB。
主要发现
- 头孢地尔MIC50和MIC90范围分别为0.125-8 mg/L和0.5-8 mg/L,98%的分离株在≤4 mg/L被抑制。
- 仅5株分离株头孢地尔MIC>4 mg/L:3株产ST2/OXA-24/40的鲍曼不动杆菌、1株产ST114/VIM-1的阴沟肠杆菌和1株产ST114/VIM-1+OXA-48的阴沟肠杆菌。
- 所有产KPC-3的肺炎克雷伯菌均对头孢地尔敏感,包括对头孢他啶/阿维巴坦耐药者。
- 铜绿假单胞菌分离株头孢地尔MIC<4 mg/L,包括对头孢洛扎/他唑巴坦耐药者。
- 嗜麦芽窄食单胞菌分离株头孢地尔MIC<4 mg/L,包括对左氧氟沙星和/或甲氧苄啶/磺胺甲噁唑耐药者。
关键数值与推荐
- 98%的分离株头孢地尔MIC≤4 mg/L。
- 5株分离株头孢地尔MIC>4 mg/L。
- 所有产KPC-3的肺炎克雷伯菌对头孢地尔敏感。
- 铜绿假单胞菌和嗜麦芽窄食单胞菌分离株头孢地尔MIC均<4 mg/L。
临床怎么用
- 头孢地尔对多重耐药革兰阴性菌(包括碳青霉烯耐药株)体外活性强,可考虑作为治疗选择。
- 对产KPC-3肺炎克雷伯菌(包括耐头孢他啶/阿维巴坦者)及耐头孢洛扎/他唑巴坦的铜绿假单胞菌,头孢地尔体外有活性。
- 对耐左氧氟沙星和/或甲氧苄啶/磺胺甲噁唑的嗜麦芽窄食单胞菌,头孢地尔体外有活性。
局限性
- 研究为体外活性检测,未提供临床疗效或安全性数据。
- 菌株仅来自西班牙南部医院,地域有限。
- 未报告药代动力学/药效学参数或耐药机制深入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR Gram-negative bacilli (MDR-GNB). OBJECTIVES: To assess the in vitro antibacterial activity of cefiderocol against a collection of MDR-GNB clinical isolates from hospitals in southern Spain. METHODS: Two hundred and thirty-one isolates of successful clones were tested: 125 Enterobacterales (121 ESBL- and/or carbapenemase-producing Klebsiella pneumoniae and 4 carbapenemase-producing Enterobacter cloacae), 80 Acinetobacter baumannii, 6 Pseudomonas aeruginosa and 20 Stenotrophomonas maltophilia. Ceftolozane/tazobactam, ceftazidime, ceftazidime/avibactam, cefepime, aztreonam, meropenem, amikacin, ciprofloxacin, colistin and tigecycline were used as comparators against Enterobacterales, P. aeruginosa and A. baumannii. Minocycline, levofloxacin and trimethoprim/sulfamethoxazole were studied against S. maltophilia instead of aztreonam, ciprofloxacin and cefepime. MICs were determined by broth microdilution according to CLSI guidelines. MIC determination was performed in CAMHB for all antimicrobials except cefiderocol, where iron-depleted CAMHB was used. RESULTS: Cefiderocol showed potent in vitro activity against the isolates analysed. MIC50 and MIC90 values were in the ranges 0.125-8 mg/L and 0.5-8 mg/L, respectively, and 98% of isolates were inhibited at ≤4 mg/L. Only five isolates showed cefiderocol MICs of >4 mg/L: three ST2/OXA-24/40-producing A. baumannii, one ST114/VIM-1-producing E. cloacae and one ST114/VIM-1 + OXA-48-producing E. cloacae. All KPC-3-producing K. pneumoniae were susceptible to cefiderocol, even those resistant to ceftazidime/avibactam. P. aeruginosa isolates showed cefiderocol MICs of <4 mg/L, including those resistant to ceftolozane/tazobactam. S. maltophilia isolates displayed cefiderocol MICs of <4 mg/L, including those resistant to levofloxacin and/or trimethoprim/sulfamethoxazole. CONCLUSIONS: Cefiderocol showed excellent activity against MDR-GNB, including carbapenem-resistant isolates, and was the most active antimicrobial tested against this collection.
引用
- Delgado-Valverde M, Conejo MDC, Serrano L, et al. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother. 2020. PMID: 32277821. doi:10.1093/jac/dkaa117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。